



Oculus to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jul 30, 2024

ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculus Holding AG (Nasdaq: OCS) ("Oculus"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculus' management will be participating at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.

Riad Sherif, M.D., Chief Executive Officer of Oculus, will participate in a panel discussion titled "Derisked Late-stage Candidates for Retinal Disorders" on August 15, 2024, at 11:00 am ET. Dr. Sherif will also deliver a virtual company presentation which will be available on-demand, on August 15, 2024, at 7:00 am ET.

Links to access the company presentation and panel discussion, when available, will be posted to the Oculus website on the [Events & Presentation](#) page under the Investors & Media section.

About Oculus

Oculus is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculus' highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; licamimab (OCS-02), a topical biologic anti-TNF α eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculus' goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculus.com

Oculus Contact

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculus.com

Investor & Media Relations

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577



Source: Oculus Holding AG